文献速递心外重症与机械循环支持

体外膜肺氧合支持在重症COVID-19中的应用

Extracorporeal Membrane Oxygenation Support in Severe COVID-19.
PubMed 文献 · Ann Thorac Surg · 2020-07-17

该研究回顾性分析了2020年3月10日至4月24日间本机构收治的重症COVID-19患者,评估ECMO支持的应用与管理。在321例插管患者中,77例(24%)接受ECMO评估,27例(8.4%)接受ECMO,均为静脉-静脉ECMO。目前生存率为96.3%,仅1例死亡,总ECMO支持时间超过350天;13例(48.1%)仍在ECMO支持中,13例(48.1%)已成功撤机,7例(25.9%)已出院。早期结果表明,合理使用ECMO可能对重症COVID-19患者临床有益。

要点

  • 重症COVID-19插管患者中8.4%需ECMO支持,均为静脉-静脉模式。
  • 本组ECMO患者生存率96.3%,总支持时间超350天仅1例死亡。
  • 无参与ECMO置管的医护人员出现症状或检测阳性。

核心结论

  • 早期结果表明,对重症COVID-19患者合理使用ECMO支持可能临床有益。

研究设计与样本

  • 回顾性队列研究,纳入2020年3月10日至4月24日评估ECMO支持的危重COVID-19患者。
  • 在321例因COVID-19插管的患者中,77例(24%)接受ECMO评估,27例(8.4%)接受ECMO。

主要发现

  • 所有患者均接受静脉-静脉ECMO支持。
  • 当前生存率为96.3%,总ECMO支持时间超过350天中仅1例死亡。
  • 13例(48.1%)仍在ECMO支持中,13例(48.1%)已成功撤机。
  • 7例(25.9%)已出院,6例(22.2%)仍在住院,其中4例呼吸室内空气。
  • 无参与ECMO置管的医护人员出现症状或检测阳性。

关键数值与推荐

  • ECMO评估标准:动脉血氧分压/吸入氧浓度比小于150 mm Hg,或pH小于7.25且动脉血二氧化碳分压超过60 mm Hg,且无限制生命的合并症。
  • 管理策略包括保护性肺通气、早期气管切开、支气管镜检查和俯卧位通气(根据临床指征)。

临床怎么用

  • 对符合氧合或通气标准且无严重合并症的重症COVID-19患者,可考虑静脉-静脉ECMO支持。
  • ECMO管理期间应结合保护性肺通气、早期气管切开、支气管镜和俯卧位等综合措施。

局限性

  • 回顾性单中心研究,样本量有限(27例ECMO患者),随访时间短,部分患者仍在ECMO或住院中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronavirus disease 2019 (COVID-19) remains a worldwide pandemic with a high mortality rate among patients requiring mechanical ventilation. The limited data that exist regarding the utility of extracorporeal membrane oxygenation (ECMO) in these critically ill patients show poor overall outcomes. This report describes our institutional practice regarding the application and management of ECMO support for patients with COVID-19 and reports promising early outcomes. METHODS: All critically ill patients with confirmed COVID-19 evaluated for ECMO support from March 10, 2020, to April 24, 2020, were retrospectively reviewed. Patients were evaluated for ECMO support based on a partial pressure of arterial oxygen/fraction of inspired oxygen ratio of less than 150 mm Hg or pH of less than 7.25 with a partial pressure of arterial carbon dioxide exceeding 60 mm Hg with no life-limiting comorbidities. Patients were cannulated at bedside and were managed with protective lung ventilation, early tracheostomy, bronchoscopies, and proning, as clinically indicated. RESULTS: Among 321 patients intubated for COVID-19, 77 patients (24%) were evaluated for ECMO support, and 27 patients (8.4%) were placed on ECMO. All patients were supported with venovenous ECMO. Current survival is 96.3%, with only 1 death to date in more than 350 days of total ECMO support. Thirteen patients (48.1%) remain on ECMO support, and 13 patients (48.1%) have been successfully decannulated. Seven patients (25.9%) have been discharged from the hospital. Six patients (22.2%) remain in the hospital, of which 4 are on room air. No health care workers who participated in ECMO cannulation developed symptoms of or tested positive for COVID-19. CONCLUSIONS: The early outcomes presented here suggest that the judicious use of ECMO support in severe COVID-19 may be clinically beneficial.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Kon ZN, Smith DE, Chang SH, et al. Extracorporeal Membrane Oxygenation Support in Severe COVID-19. Ann Thorac Surg. 2020. PMID: 32687823. doi:10.1016/j.athoracsur.2020.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。